| Literature DB >> 36234885 |
Fei Cheng1,2, Jianping Wu1,3, Yan Zhang1, Yuyan Wang1,3, Guihua Li1,3, Hongliang Zeng2, Xiaoai He4, Guiming Deng5, Jianbin Tan1,6, Hongping Long5, Puhua Zeng2, Yiheng Liu4, Gangzhi Zhu4, Zuhui Chen3, Kangping Xu1,3,5,6.
Abstract
Five new furofurans lignans, Brasesquilignan A-E (1-5), were isolated from the aqueous ethanol extract of Selaginella braunii Baker. Their structures were elucidated by extensive analysis of NMR and HRESIMS data. Their absolute configurations were determined by CD spectra, enzymatic hydrolysis, and GCMS analysis. Furthermore, all compounds were evaluated for anti-proliferative activities against various human cancer cellsin vitro. Compounds 2 and 3 exhibited weak inhibitorypotency against five human cancer cells.Entities:
Keywords: Selaginella braunii Baker; Selaginellaceae; anti-proliferativeactivity; furofurans lignans
Mesh:
Substances:
Year: 2022 PMID: 36234885 PMCID: PMC9572557 DOI: 10.3390/molecules27196349
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Structures of compounds 1–5.
1H NMR (500 MHz) data of 1–5 in DMSO-d6.
| Position | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| 1 | |||||
| 2 | 6.87, brs | 6.86, brs | 6.88, d (1.6) | 6.70, m | 6.89, d (1.4) |
| 3 | |||||
| 4 | 6.78, m | 6.78, m | 6.70, m | 6.74, d (1.6) | |
| 5 | 6.72, d (8.1) | 6.59, m | |||
| 6 | 7.03, brs | 7.03, brs | 6.75, d (1.6) | 6.82, brs | 6.76, d (1.6) |
| 7 | 4.63, d (4.1) | 4.62, d (4.0) | 4.63, t (4.2) | 4.60, m | |
| 8 | 3.06, m | 3.05, m | 3.06, m | 3.47 overlapped | 3.03, m |
| 9a | 4.13, m | 4.15, m | 4.13, m | 3.88, m | 4.13, m |
| 9b | 3.73, m | 3.72, m | 3.73, m | 3.57, m | 3.73, m |
| 1′ | |||||
| 2′ | 6.75, m | 6.73, m | 6.82, brs | 6.60, brs | |
| 3′ | 6.97, d (1.9) | 6.78, dd (1.6, 8.0) | |||
| 4′ | |||||
| 5′ | 6.85, dd (8.6, 1.8) | 6.97, d (1.5) | 6.65, d (8.0) | ||
| 6′ | 6.89, d (1.4) | 6.88, brs | 7.06, d (8.5) | 6.70, m | 6.60, brs |
| 7′ | 4.61, d (4.1) | 4.64, d (4.0) | 4.63, t (4.2) | 4.63, d (6.4) | 4.60, m |
| 8′ | 3.06, m | 3.05, m | 3.06, m | 2.19, m | 3.03, m |
| 9′a | 4.13, m | 4.15, m | 4.13, m | 3.68, m | 4.13, m |
| 9′b | 3.73, m | 3.72, m | 3.73, m | 3.46 overlapped | 3.73, m |
| 1″ | |||||
| 2″ | 6.97, d (1.6) | 6.96, brs | 6.73, brs | ||
| 3″ | 6.87, brs | ||||
| 4″ | |||||
| 5″ | 6.73, m | 6.75, m | 6.74, brs | ||
| 6″ | 6.78, m | 6.78, m | 6.86, brs | 6.71, brs | |
| 7″ | 3.61, m | 3.58, m | 3.43, m | 3.59, m | 4.11, m3.40 overlapped |
| 8″ | 5.47, d (7.4) | 5.45, d (7.4) | 5.51, d (6.5) | 5.46, d (7.2) | 4.12, m |
| 9″a | 3.97, m | 3.72, m | 3.72, m | 3.95, m | 4.11, m |
| 9″b | 3.72, m | 3.04, m | 3.63, m | 3.06, m | 3.40 overlapped |
| 1‴ | 4.25, d (7.8) | 4.24, d (7.7) | 4.89, d (7.4) | 4.23, d (7.8) | |
| 2‴ | 3.00, m | 2.97, m | 3.25, m | 3.00, m | |
| 3‴ | 3.08, m | 3.05, m | 3.25, m | 3.11, m | |
| 4‴ | 3.06, m | 3.06, m | 3.14, m | 3.06, m | |
| 5‴ | 3.18, m | 3.16, m | 3.26, m | 3.10, m | |
| 6‴ | 3.65, m | 3.65, m | 3.64, m | 3.66, m | |
| –OCH3 | (3-) 3.79, brs | (3-) 3.78, brs | (4-) 3.77, brs | (3-) 3.76, brs | (3″-) 3.71, brs |
| (3′-) 3.76, brs | (3′-) 3.76, brs | (2′-) 3.75, brs | (2″-) 3.74, brs | (3′-) 3.74, brs | |
| (5′-) 3.76, brs | (5′-) 3.75, brs | (3″-) 3.80, brs | (6″-) 3.74, brs | (4″-) 3.75, brs | |
| (5″-) 3.76, brs | |||||
| 7-CH3 | 1.07, d (6.7) | ||||
| 1″″ | 4.25, d (7.7) | ||||
| 2″″ | 2.98, m | ||||
| 3″″ | 3.05, m | ||||
| 4″″ | 3.05, m | ||||
| 5″″ | 3.33, m | ||||
| 6″″ | 3.50 overlapped |
13C NMR (125 MHz) data of 1–5 in DMSO-d6.
| Position | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| 1 | 135.2 | 135.2 | 132.6 | 134.5 | 145.1 |
| 2 | 111.0 | 110.9 | 110.9 | 113.2 | 110.9 |
| 3 | 144.0 | 144.0 | 148.0 | 143.9 | 146.4 |
| 4 | 119.2 | 119.2 | 146.4 | 115.5 | 119.1 |
| 5 | 147.3 | 147.3 | 115.6 | 146.0 | 122.1 |
| 6 | 115.6 | 115.6 | 119.0 | 117.6 | 114.1 |
| 7 | 85.9 | 85.9 | 85.5 | 79.6 | 85.6 |
| 8 | 54.3 | 54.2 | 54.0 | 67.5 | 54.0 |
| 9 | 71.5 | 71.4 | 71.5 | 72.3 | 71.4 |
| 1′ | 146.6 | 146.4 | 146.6 | 135.1 | 135.3 |
| 2′ | 115.6 | 115.7 | 149.5 | 110.4 | 104.1 |
| 3′ | 148.0 | 148.0 | 110.9 | 119.1 | 148.0 |
| 4′ | 132.0 | 132.1 | 135.7 | 146.1 | 129.8 |
| 5′ | 148.1 | 148.1 | 118.3 | 110.9 | 115.6 |
| 6′ | 111.0 | 110.9 | 115.6 | 118.7 | 104.1 |
| 7′ | 85.6 | 85.6 | 85.9 | 82.3 | 85.8 |
| 8′ | 54.0 | 54.0 | 54.3 | 52.9 | 54.1 |
| 9′ | 71.3 | 71.4 | 71.5 | 59.0 | 71.5 |
| 1″ | 129.5 | 129.5 | 129.4 | 129.2 | 129.1 |
| 2″ | 111.1 | 110.9 | 147.3 | 147.8 | 115.6 |
| 3″ | 147.3 | 147.3 | 115.6 | 146.8 | 148.4 |
| 4″ | 132.5 | 132.6 | 135.0 | 132.4 | 153.6 |
| 5″ | 115.7 | 115.6 | 144.0 | 115.6 | 148.4 |
| 6″ | 119.2 | 119.1 | 110.9 | 148.0 | 104.1 |
| 7″ | 51.0 | 51.0 | 53.9 | 50.9 | 61.9 |
| 8″ | 87.4 | 87.2 | 87.2 | 87.3 | 84.0 |
| 9″ | 70.6 | 70.6 | 63.4 | 70.5 | 62.2 |
| 1‴ | 103.3 | 103.2 | 100.5 | 103.2 | |
| 2‴ | 73.9 | 73.9 | 73.6 | 73.9 | |
| 3‴ | 77.3 | 77.2 | 77.3 | 77.2 | |
| 4‴ | 70.6 | 70.4 | 70.1 | 70.5 | |
| 5‴ | 77.4 | 77.3 | 77.5 | 77.4 | |
| 6‴ | 61.5 | 61.5 | 61.0 | 61.5 | |
| -OCH3 | (3-) 56.2 | (3-) 56.2 | (4-) 56.2 | (3-) 56.1 | (3″-) 56.1 |
| (3′-) 56.1 | (3′-) 56.1 | (2′-) 56.2 | (2″-) 56.0 | (3′-) 56.0 | |
| (5′-) 56.1 | (5′-) 56.1 | (3″-) 56.1 | (6″-) 56.0 | (4″-) 56.4 | |
| (5″-) 56.5 | |||||
| 7-CH3 | 22.0 | ||||
| 1″″ | 103.9 | ||||
| 2″″ | 73.8 | ||||
| 3″″ | 77.2 | ||||
| 4″″ | 68.9 | ||||
| 5″″ | 76.3 | ||||
| 6″″ | 67.5 |
Figure 2The CD spectra of compounds 1–5 (MeOH).
Figure 3Key 1H-1H COSY and HMBC correlations of compounds 1–5.
Anti-proliferative activity ofall compoundsagainst five human cancer cell linesin vitro.
| Compound | IC50 (μM) | ||||
|---|---|---|---|---|---|
| SK-MEL-28 | A375 | A549 | MCF-7 | MDA-MB-231 | |
|
| N/A | N/A | N/A | 93.69 ± 5.54 | N/A |
|
| 48.30 ± 5.29 | 35.12 ± 2.54 | 27.82 ± 2.38 | 22.09 ± 2.39 | 44.02 ± 2.32 |
|
| 56.82 ± 4.83 | 63.57 ± 1.49 | 38.88 ± 2.85 | 31.26 ± 1.14 | 53.56 ± 1.44 |
|
| N/A | N/A | N/A | N/A | N/A |
|
| N/A | N/A | N/A | N/A | N/A |
| STS | 0.04 ± 0.008 | 0.06 ± 0.006 | 0.4 ± 0.11 | 0.2 ± 0.04 | 0.03 ± 0.005 |
N/A: Not active; STS: Staurosporine used as a positive control.